Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 11, 2023

SELL
$40.65 - $59.54 $1.26 Million - $1.85 Million
-31,100 Reduced 8.0%
357,765 $16.8 Million
Q1 2023

May 12, 2023

BUY
$37.27 - $46.57 $264,617 - $330,647
7,100 Added 1.86%
388,865 $16.3 Million
Q4 2022

Feb 13, 2023

SELL
$32.2 - $43.61 $1.53 Million - $2.07 Million
-47,548 Reduced 11.08%
381,765 $14.6 Million
Q3 2022

Nov 10, 2022

SELL
$32.28 - $43.27 $1.49 Million - $2 Million
-46,287 Reduced 9.73%
429,313 $16.8 Million
Q2 2022

Aug 12, 2022

BUY
$27.52 - $37.99 $13.1 Million - $18.1 Million
475,600 New
475,600 $15.4 Million

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $326M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Finepoint Capital LP Portfolio

Follow Finepoint Capital LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Finepoint Capital LP, based on Form 13F filings with the SEC.

News

Stay updated on Finepoint Capital LP with notifications on news.